Tissue Diagnostics Market 2023 – Drivers, Restraints, Opportunities and Challenges

Tissue Diagnostics Market

The global tissue diagnostics market is growing significantly due to increasing prevalence of cancer, and technological advancements in tissue diagnostics. Massive unexplored tissue diagnostics market in emerging economies and lack of efficient diagnostic procedures are creating ample opportunities for the global tissue diagnostics market to grow at a considerable rate in the coming years. The advanced research and development facilities and increasing investment by large pharmaceutical companies in small tissue diagnostics companies are propelling the demand for cost effective and efficient tissue diagnostics instruments.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/tissue-diagnostics-market/report-sample

A recent trend observed in thetissue diagnostics industry is increasing usage of immunohistochemistry products as companion diagnostics devices. Increasing prevalence of cancer has fuelled the demand of better diagnostic techniques, which could detect cancer in the earliest stage. According to the WHO, in 2012, there were 14 million new cancer cases and 8.2 million cancer related deaths worldwide.

The global tissue diagnostics market is categorized on the basis of product type, technology, application, and end-user. Based on product type, the tissue diagnostics market can be categorized as instruments and consumables. On the basis of technology, the tissue diagnostics market is categorized as digital pathology and workflow management, in situ hybridization, immunohistochemistry, and special staining. The immunohistochemistry segment leads the global tissue diagnostics market in terms of market size.

Explore Report at: https://www.psmarketresearch.com/market-analysis/tissue-diagnostics-market

Geographically, North America will be leading the global tissue diagnostics market in the coming years due to high prevalence of cancer cases, high healthcare expenditure, and presence of a large number of hospitals and pharmaceutical companies. Additionally, the legislative reform of Affordable Care Act in the U.S. is also expected to drive the North American market in the coming years. Asia-Pacific is the fastest growing region in the global tissue diagnostics market. The major reasons for the fastest growth in the region are aging population, increasing disposable income, and improving healthcare infrastructure. Moreover, the tissue diagnostics marketis growing due to large unexplored tissue diagnostics market and large population base suffering with cancer in the emerging economies, such as India and China, of Asia-Pacific region.

Some of the major players operating in the global tissue diagnostics market are F. Hoffmann-La Roche AG., Sigma Aldrich Corporation, Abbott, Biogenex Laboratories, BioSB, Cell Signalling Technology Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, GE Healthcare, and Siemens Healthcare.

Advertisements

Fibrin Glue Market Drivers, Restraints, Opportunities, and Challenges

Fibrin Glue MarketThe global fibrin glue market is likely to grow significantly during the forecast period, mainly due to increasing number of surgical procedures and burn cases, and rising healthcare expenditure. According to the data provided by the World Bank, 30,537 surgeries were performed per 100,000 population, in 2012, in the U.S. Similarly, in 2015, number of surgical procedures performed in Australia were 28,907 per 100,000 population.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/fibrin-glue-market

Fibrin glue is used in various types of surgeries. Fibrin glue is also used in burn cases during plastic surgeries and surgery of the burned body parts. According to WHO, approximately 265,000 deaths every year are caused by burns. Additionally, increasing prevalence of chronic diseases and low chances of complications associated with these products and rise in the number of road accidents also contributes to the growth of the overall market. However, increasing minimally invasive procedures and stringent regulatory requirements are some of the key factors restraining the growth of global fibrin glue market.

In October 2016, Ethicon received USFDA approval for an expanded indication for EVARREST Fibrin Sealant Patch. The expanded indication supported the use of EVARREST as an adjunctive hemostat for a broad range of patients and surgical situations. The expanded indication was based on a cardiovascular clinical study that demonstrated EVARREST’s superior hemostatic efficacy. The expanded indication is major trend being observed in the global fibrin glue market, which has led to the increase in the use of the fibrin glues.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/fibrin-glue-market/report-sample

Some of the key players operating in the global fibrin glue market include Vivostat A/S, Kaketsuken, Johnson & Johnson, Baxter International Inc., CSL Behring, Zimmer Biomet Holdings, Inc., Takeda Pharmaceutical Company Limited, Mallinckrodt Plc, Shanghai RAAS Blood Products Co. Ltd. and Hualan Biological Engineering Inc.

Bioinformatics Market – Analysis, Size and Forecast till 2023

Bioinformatics MarketThe introduction and adoption of cloud computing and nanopore technology are expected to offer numerous opportunities in the global bioinformatics market. The nanopore technology has been projected for getting used in the study of crop science, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins and small molecules with a range of applications in personalized medicine, and scientific research.

To know more visit: https://www.psmarketresearch.com/market-analysis/bioinformatics-market

Bioinformatics is a discipline that deals with the retrieval, storage, processing, management and analysis of organic information through computational techniques. Bioinformatics plays an important role in drug innovation and improvement. The involvement of bioinformatics in storing, retrieving, analyzing and forming biological information helps in efficiently managing enormous database associated with drug innovation and development.

The global bioinformatics market can be broadly segmented on the basis of applications, products and services, sectors and geographies. On the basis of products & services the bioinformatics market can be broadly bifurcated into bioinformatics platforms, bioinformatics knowledge management tools and bioinformatics services. The bioinformatics knowledge management tools segment can be further divided into specialized tools and generalized tools. The bioinformatics platforms are further sub-divided into sequence alignment platforms, sequence analysis platforms, structural & functional analysis platforms and sequence manipulation platforms. The bioinformatics services segment is again segmented into database & management, sequencing services and data analysis.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/bioinformatics-market/report-sample

Some of the key competitors within the global bioinformatics market include Tripos, LP, Affymetrix, Inc, Agilent Technologies, Illumina, Inc., Helicos Biosciences Corporation, IBM Life Sciences, Thermo Fisher Scientific Inc, Rosetta Inpharmatics LLC, Celera and others.

Healthcare/Medical Simulation Market – Research Report, Size & Growth, 2023

 

Healthcare Simulation Market

The global healthcare/medical simulation market is growing significantly due to technological advancements and increasing demand for minimally invasive procedures. Massive unexplored healthcare/medical simulation market in emerging economies and lack of service providers are creating ample opportunities for the global healthcare/medical simulation market to grow at a considerable rate in the coming years. However, lack of adequate input data for medical simulation models is a major challenge in the global healthcare and medical simulation market. Medical simulation trains medical professionals to minimise errors during surgical procedures by using advanced techniques of simulation. The simulated animations help students to understand the complexity of medical procedures through computer-based virtual patients.

Explore Report at: https://www.psmarketresearch.com/market-analysis/healthcare-simulation-market

Adoption of medical simulation technology in hospitals and academic institutes worldwide in order to reduce the medical errors and improve patient safety is a trend in healthcare/medical simulation market. Deaths occurring due to medical mistakes are major concern across the globe. According to a report published in September 2013, in the Journal of Patient Safety, more than 440,000 people die every year due to preventable medical errors. Healthcare simulation may simulate critical medical conditions without any harm to patients; this in turn helps medical professionals to evaluate their practices and reduce their mistakes. Medical simulation is capable of reproducing critical events over and over again and hence, explores consequences of each error or mistake made.

Geographically, North America will be leading the global healthcare/medical simulation market in the coming years, due to technological advancements, high healthcare expenditure, and presence of a large number of hospitals and academic institutions. In addition, Patient Safety and Quality Improvement Act in the U.S. is also driving its market in North America region. Asia-Pacific is the fastest growing region in the global healthcare/medical simulation market. The major reasons for the fastest growth in the region are improving healthcare infrastructure and increasing demand for minimally invasive procedures.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/healthcare-simulation-market/report-sample

Some of the major players operating in the global healthcare/medical simulation market are Laerdal Medical As, 3D Systems, Inc., CAE, Inc., Kyoto Kagaku Co., Ltd., Limbs & Things, Ltd., Gaumard Scientific Company, Inc., Simulab Corporation, Surgical Science Sweden Ab, and Mentice Ab.

Endometrial Cancer Treatment Market Pipeline Analysis, Share and Forecast to 2023

Endometrial Cancer Treatment Market

The global endometrial cancer treatment market is expected to witness growth due to unmet need of treatment, technological advancement in cancer therapeutics and diagnostic test, rising prevalence of cancer, and sedentary lifestyle of women. In addition, increasing awareness about the uterine diseases and the available therapies and increasing healthcare expenditure is also driving the growth of global endometrial cancer treatment market.

Explore Full Report at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market

The pharmaceutical companies are actively involved in the endometrial cancer research and development. AEterna Zentaris, Inc., is developing Zoptrex (zoptarelin doxorubicin), a Phase III clinical trial drug candidate for the treatment of endometrial cancer. In October 2016, the company entered into licensing agreement with Specialized Therapeutics Asia, a biopharmaceutical company, for the marketing of zoptarelin doxorubicin in Australia and New Zealand.

Endometrial cancer is an abnormal growth of uterus, in which inner lining of the uterus known as endometrium got affected. The American Cancer Society estimated that in year 2016, about 60,050 new cases of endometrial cancer would be diagnosed in the U.S. and about 10,470 women would die from cancers of the uterine body. The sign and symptoms of endometrial cancer is abnormal vaginal bleeding. It is most often diagnosed by pelvic ultrasound and transvaginal ultrasound. An endometrial biopsy is also preferred in postmenopausal women with endometrial cancer.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/toc-sample

Some of the key players operating in the global market are Bristol-Myers Squibb Company, Merck & Co., Inc., Ariad Pharmaceuticals Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories.

Immune Checkpoint Inhibitors Market Analysis, Size & Forecast to 2023

Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market is expected to witness significant growth as these are proven to be more effective therapy in shrinking tumor in higher proportion of patients, as compared to other immunotherapies. Immune checkpoint inhibitors are applicable to a wider range of tumor types such as advanced or metastatic non-small cell lung cancer, renal cancer and melanoma. These inhibitors lower the rate of severe toxicities and immune-mediated side-effects. These are also convenient to administer and yield a good response rate of any single-agent immunotherapy.

Explore Report at: https://www.psmarketresearch.com/market-analysis/immune-checkpoint-inhibitors-market

The pharmaceutical companies are actively involved in the research and development of drug for immune checkpoint inhibitors. The pipeline of immune checkpoint inhibitors is rich with more than 50 drugs. In November 2016, Bristol-Myers Squibb Company and Infinity Pharmaceuticals collaborated to check the efficacy of combination of Opdivo (a PD-1 inhibitor monoclonal antibody) and IPI-549 (a phosphoinositide-3-kinase gamma inhibitor) in patients with advanced solid tumors.

Immune checkpoint inhibitors are showing good efficacy with PD-1 and PD-L1 inhibitors and CTLA-4 inhibitors. Yervoy, an anti-CTLA-4 product of Bristol-Myers Squibb Company got approved in the year 2011. The increased use of combination therapy of PD-1 and PD-L1 inhibitors represent a new signal of immunotherapeutics, which is expected to alter the standard of care for cancer across the globe. However, the development of effective immunotherapy presents some challenges due to complex pathophysiology of cancer and difficulty in managing treatment related toxic effects, which is expected to hamper the growth of the global market to some extent.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/immune-checkpoint-inhibitors-market/toc-sample

Some of the key players operating in the global market are Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and TG Therapeutics, Inc.

Nonalcoholic Steatohepatitis Therapeutics Market – Analysis, Size, Growth and Forecast to 2023

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market

The global nonalcoholic steatohepatitis therapeutics market is expected to witness significant growth due to current unmet medical need of NASH, scarcity of the permanent treatment of the disease, increasing prevalence of obesity, and high demand for safe and effective medication. The regulatory bodies are supporting the NASH market by providing designations and funding for speeding up the drug development process. In March 2015, obeticholic acid, an investigational Phase III clinical trial drug candidate of Intercept Pharmaceuticals Inc., received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of patients with NASH.

Explore Report at: https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market

The pipeline of NASH therapeutics is rich with more than 50 drugs. The pharmaceutical companies are actively involved in the research and development of drug for NASH. In June 2016, The Zydus Cadila initiated Phase III clinical trials of Saroglitazar to study its effect in adult NASH patients.

A large number of pharmaceutical companies are investing huge capital for the development of NASH therapeutics. However, certain factors such as unknown etiology, complex pathophysiology, and high treatment cost of NASH are expected to hamper the growth of the global market during the forecast period.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market/toc-sample

Geographically, North America is expected to be the largest market for NASH therapeutics owing to the large number of research and development activities, high healthcare expenditure and high incidence of obesity. The U.S. contributed largest revenue to the North American market and it is expected to remain the largest market globally, during the forecast period.

Some of the key players operating in the global NASH therapeutics market are Genfit SA, Gilead Sciences, Inc., Novo Nordisk A/S, Intercept Pharmaceuticals, Inc., Enzo Biochem, Inc., Raptor Pharmaceutical Corp., Conatus Pharmaceuticals Inc., Zydus Cadila Healthcare Limited., Novartis AG, and Shire plc.

Blood Collection Market – Trends, Analysis and Research Report, 2023

Blood Collection Market

The global blood collection market is witnessing considerable growth due to increasing geriatric population, increasing number of accidental cases and growing surgical procedures. Moreover, growing prevalence of chronic diseases including cancer, cardiovascular disease, infectious diseases, autoimmune diseases, diabetes mellitus, and infectious diseases is supporting the growth of the market. Based on product type, the blood collection needle and syringe segment lead the market. The increasing demand of needle and syringe for blood collection across the globe, owing to their easy availability and ease of use, is driving the growth of this segment. In addition, rising initiatives undertaken by government associations to boost awareness about blood donations and advanced features of blood collection products are also supporting to the growth of this market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/blood-collection-market

The use of RFID technology in blood banks and transfusion medicine has the potential to improve operational efficiency. It helps in providing patient safety at point of care by automatically identifying, reconciling, and tracking blood products throughout the blood supply chain. The increasing use of radiofrequency identification (RFID) and needle free devices is expected to create opportunities for the manufacturers of blood collection products. However, risk associated with blood transfusions and growing needlestick injuries are the key factors hampering the growth of the global market.

Geographically, North America has been the largest market for blood collection, owing to increased awareness, established healthcare industry, and easy increasing prevalence of infectious and non-infectious diseases in the region. The U.S. contributed largest revenue to the North American as well as global blood collection market. The presence of large number of diagnostic laboratories and hospitals, and increasing prevalence of people with blood disorders are the key growth driving factors for the U.S. blood collection market.

Request For Table of Content at: https://www.psmarketresearch.com/market-analysis/blood-collection-market/toc-sample

The key players operating in the global blood collection market are Abbott Laboratories Inc., Becton, Dickinson and Company, Terumo Corporation, Sarstedt AG & Co., Nipro Medical Corporation, Qiagen, Haemonetics Corporation, Greiner Holding AG and F.L. Medical SRL.

Cartilage Repair Market Size, Share and Forecast to 2023

Cartilage Repair MarketThe global cartilage repair market is witnessing considerable growth due to increasing geriatric population, increasing obesity, increasing healthcare expenditure, and growing sports related injuries. Moreover, increase in innovative product launches and growth of medical tourism leading to awareness about the cartilage treatment modalities across the globe is supporting the growth of the market. Based on the treatment modalities, cell-based approaches segment is expected to grow at the fastest rate during the forecast period, due to long term results of this treatment.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cartilage-repair-market

Obesity is a serious health concern in the U.S. The increasing prevalence of obesity is driving the growth of the cartilage repair market in the U.S. According to CDC, during 2011-2012, 35.1% of adult aged 20 years or above were obese. In addition, as published by the Organization for Economic Cooperation and Development (OECD) in the year 2014, the obesity rate in Germany increased from 11.5% in 1999 to 14.7% in 2009. This increase in obesity rate leads to increase in demand for liposuction procedures, which is further accelerating the market growth.

Europe has been the second largest market for cartilage repair, where the market is driven by the increasing demand for cell-based approaches, increasing healthcare expenditure and launch of novel products. In 2015, Germany led the European cartilage repair market and it is also expected to grow at the fastest rate in Europe, during the forecast period. Globally, the cartilage repair market is expected to witness the fastest growth in Asia-Pacific during the forecast period, attributed to the increasing per capita income leading to improved standard of living, increasing healthcare spending, growing demand for better quality medical care, and awareness about cartilage repair treatments in the region.

Request For Table of Content at: https://www.psmarketresearch.com/market-analysis/cartilage-repair-market/toc-sample

The key players operating in the global cartilage repair market are Zimmer Biomet Holdings, Inc., Johnson & Johnson, Vericel Corporation, Smith & Nephew PLC, Osiris Therapeutics, Inc., RTI Surgical, Conmed Linvatec, B. Braun Melsungen AG, Anika Therapeutics S. R. L.  and Arthrex, Inc.